Ivor Elrifi, Chief Executive Officer at Tiziana Life Sciences Ltd (TLSA), bought 667,000 shares at $1.00 ($667K) on 2026-08-03, disclosed to the SEC on 2026-08-05.
CEO Ivor Elrifi purchased $667,000 of shares at $1.00, marking the largest insider purchase in the company's history and signaling strong conviction in the stock's recovery. This significant capital commitment comes as the company reports positive clinical data for its lead drug candidate, foralumab.
The stock is trading near the bottom of its 52-week range at $0.98, down 16.04% over the last 30 days and 32.72% from its 52-week high of $1.46.
Something here stands out, but not much.